A plain-language look at the science behind Lilly's oral GLP-1 pill, aimed at people finding weight harder to manage in middle age.
Recap by typeshit. Full story at Blavity on MSN.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
GoodRx keeps a running page on peptide regulation news, with a focus on what the FDA is doing about compounding pharmacies.
The large study looked at people with both schizophrenia and diabetes taking drugs like Ozempic. Quartz notes the findings come with caveats.
Loading…